erythromycin has been researched along with abiraterone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Archakov, AI; Dmitriev, AV; Filimonov, DA; Gilep, AA; Haurychenka, YI; Kuzikov, AV; Masamrekh, RA; Shcherbakov, KA; Shkel, TV; Shumyantseva, VV; Strushkevich, NV; Usanov, SA; Veselovsky, AV; Zavialova, MG | 1 |
2 other study(ies) available for erythromycin and abiraterone
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
In vitro interactions of abiraterone, erythromycin, and CYP3A4: implications for drug-drug interactions.
Topics: Androstenes; Anti-Bacterial Agents; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Erythromycin; Humans; Hydroxylation; Molecular Docking Simulation | 2020 |